CD8A and neoplasm: Our eEF2K knockdown tumor model also confirmed the enhanced efficacy of PD-1 mAb therapy in vivo, and co-treatment with CD8 T cell elimination antibody weakened this antitumor effect, suggesting that CD8+ T cells contributed to the antitumor responses of the combination therapy of eEF2K inhibition with PD-1 blockade.